What we passed on, and whether we were right
This page lists every candidate that has left the live board, and what became of it. A candidate leaves the board when its catalyst date (the date of its big event) has passed, or when its prediction has been settled (checked against what really happened). The page answers two questions. First, how many screened candidates became a full analysis, and how did those analyses turn out? Second, were the candidates we dismissed dismissed for good reasons? To judge a dismissal we need a primary source (the original document, such as a company announcement). This page never guesses an outcome. It leaves the outcome blank until someone looks it up with a data connector (a tool that fetches data from an outside source).
NOT CITABLE: for screening only
This board is a quick, low-cost ranking. It is not an analysis. Do not use any claim from this
board in a program analysis unless it is checked again there (framework/02-connectors.md § Triage
pass). The board is only for deciding what to analyse next. It does not support a claim by itself.
Archived
20
no longer on the live board
Became an analysis
14
of 20 archived
Dismissed
0
of the archived candidates
Settled
11
prediction checked against the result
Dismissal reasons
Each reason comes from a fixed list of tags, shown with how often it was used. Later we will look for patterns here. Adjusting the A/B/C/D tiers from this is future work. It waits until there are at least 20 dismissals across 3 screens (ROADMAP.md).
Mislabelled row
0
The row's stage or event label contradicts its own note.
Date conflict
0
catalyst_date_text disagrees with the note's own timing.
Not a binary
0
Interim, additional data, or an endpoint already met.
Financing first
0
Runway ends at or before the event; a raise comes first.
Diluted materiality
0
Partner-run, multi-asset or revenue-generating, so one readout cannot move it.
Duplicate exposure
0
The same event is already reachable through another row.
Already priced
0
The run-up is spent, or a larger event lands first.
Uninvestable
0
Share count, liquidity or capitalisation makes the equity untradeable regardless of the data.
Outside window
0
The real event falls before or after the screened window.
Base rate
0
Indication base rate or a failed sister trial argues against it.
Other
0
Anything else. The note carries the whole argument.
No dismissal has reached this page yet. A dismissed candidate only appears here after its catalyst
date (the date of its big event) has passed or its prediction has been settled. Dismissals that are
still current are on /triage. The reasons above are the full list from
framework/02-connectors.md § Triage pass. The counts fill in as screens lead to decisions and
those decisions get older than their event.
Archived candidates
What became of every candidate that left the live board
| Tier | Ticker | Drug | Indication | Catalyst | Why archived | Dismissal | What it became |
|---|---|---|---|---|---|---|---|
| B | CGEM | Zipalertinib | 1L NSCLC (REZILIENT3) | Q4 2026 | the prediction has been settled | — | Analysed
view analysis →
Settled: positive — the top-line release the definition settles on (Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics, 2026-08-12, 'Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer', furnished as Exhibit 99.1 to Cullinan's 8-K) states that REZILIENT3 'met its primary endpoint of progression-free survival (PFS) at a planned interim analysis' and that 'the study demonstrated a statistically significant and clinically meaningful improvement in PFS in the zipalertinib containing arm', against platinum-based chemotherapy alone. The release does not name who assessed PFS. The registry lists the primary outcome as 'Part A and Part B: Progression-free survival (PFS) by blinded independent central review (BICR)', and the Part B comparator as 'pemetrexed and a platinum agent (either carboplatin or cisplatin)'. So the release's 'primary endpoint of PFS' is BICR-assessed PFS against pemetrexed-platinum, and every clause of the definition is met by the top-line itself. Full data (Cullinan 8-K of 2026-09-14; IASLC 2026 World Conference on Lung Cancer, Presidential Symposium, 2026-09-14): at the pre-planned interim efficacy analysis after 122 PFS events, median PFS 14.5 vs 8.5 months, hazard ratio 0.50 (95% CI 0.34-0.73), P=0.00015, in 279 randomised patients (140 vs 139). The September primary documents do not repeat 'BICR'. Three verbatim reports of the presentation (OncLive, ecancer, HMP Global Learning Network; secondary) state that the primary endpoint and the 14.5-month median were by blinded independent central review, and OncLive reports that the interim crossed the prespecified boundary for superiority (primary analysis planned at 162 events; data cutoff 2026-05-29). Secondary results: objective response rate 65.0% vs 40.3% (P<0.0001); median duration of response 14.2 vs 9.9 months; interim overall survival hazard ratio 0.72 (95% CI 0.42-1.23) at 30% maturity. Grade 3 or higher adverse events 87.1% vs 54.4%, mostly haematologic (58.6% vs 28.7%). (+1.91%) |
| C | RARE | GTX-102 | Angelman syndrome (ASPIRE) | H2 2026 | the prediction has been settled | — | Analysed
view analysis →
Settled: miss — ASPIRE missed its primary (Bayley-4 cognitive raw score) and key secondary (MDRI) endpoints vs sham (-42.4%) |
| C | SXTP | Arakoda (tafenoquine) | Babesiosis (hospitalized, interim) | October 6, 2026 | the catalyst date has passed | — | Screened |
| A | MNOV | MN-001 (tipelukast) | Hypertriglyceridemia and NAFLD due to T2DM | Q3 2026 | the catalyst date has passed | — | Analysed
view analysis →
Settled: miss — neither co-primary was met at Week 24: liver fat by CAP score p=0.2438 and fasting serum triglycerides p=0.113 vs placebo (triglycerides were significant only at Week 4, p=0.015, which is not a co-primary timepoint) (-23.14%) |
| A | TLSA | Intranasal Foralumab (anti-CD3 mAb) | Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) | Late Q3 2026 | the catalyst date has passed | — | |
| A | TYRA | Dabogratinib (TYRA-300) | Low-grade, intermediate risk non-muscle invasive bladder cancer (IR NMIBC) | September 2026 | the catalyst date has passed | — | Analysed
view analysis →
Settled: miss — pooled 3-month CR 46% (12/26) vs the ≥60% bar; safety clean (-17.75%) |
| A | ARCT | ARCT-810 | Ornithine transcarbmylase (OTC) deficiency | Q3 2026 | the catalyst date has passed | — | Analysed
view analysis →
Settled: miss — the disclosure the definition settles on (Arcturus 8-K of 2026-09-23, with its presentation and its press release 'Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0 Next-Generation mRNA Delivery Platform') meets clause (a) and fails clause (b). (a) holds: no serious adverse events among the 8 participants (0.3 mg/kg n=4, 0.5 mg/kg n=4) and no hyperammonaemia events of special interest. Two Grade 3 non-serious asymptomatic transaminitis events 'resolved without additional intervention after stopping study drug'; the 2026-08-25 SSIEM poster adds that one participant 'only received 4 doses of investigational medication due to elevated transaminases'. One participant discontinued after a single dose for a non-serious Grade 2 IV infiltration. Neither event is called dose-limiting, no hold or dosing restriction is disclosed, and both dose cohorts completed dosing. (b) fails: Arcturus does not state that ARCT-810 will advance to a registrational or Phase 3 study, and reports no End-of-Phase-2 interaction for it. The regulatory plan is for a different product. After a June 2026 FDA Type C meeting on ARCT-2601 (the OTC mRNA in the next-generation LUNAR 2.0 lipid), Arcturus plans an IND in 4Q 2026, dosing of 3 to 6 patients aged 12 and over in the ongoing ARCT-810 Phase 2 under an amended protocol near year-end, and then a Phase 2/3 paediatric study of ARCT-2601 in H2 2027; the FDA's stated path is to 'Proceed to an adequate and well-controlled pivotal trial if the initial data are favorable'. That is a further Phase 2 step before any pivotal study, for a product other than ARCT-810. Efficacy was reported only as group means of 3 to 4 participants, with no statistics: first-morning fasting ammonia -19% (0.3 mg/kg) and -42% (0.5 mg/kg), and glutamine -17% and -25%, Day 60 against baseline. The ureagenesis (relative urea function) results were not reported. (+1.05%) |
| A | DWTX | Halneuron | Chemotherapy-induced neuropathic pain | Q3 2026 | the catalyst date has passed | — | |
| A | EVMN | EVO756 (MRGPRX2 Antagonist) | Moderate-To-Severe Atopic Dermatitis | Q3 2026 | the catalyst date has passed | — | Analysed
view analysis →
Settled: miss — primary endpoint (% change in EASI at Week 12) not met at any dose; EVO756 not advanced in AD (-15.58%) |
| A | IRON | DISC-3405 (formerly MWTX-003) | Polycythemia vera | Q3 2026 | the catalyst date has passed | — | Analysed
view analysis →
Settled: positive — 61.5% phlebotomy-free through 26 weeks (Cohort A, n=13), phlebotomies 4.0→0.6 (p<0.0001), well tolerated, advancing (-5.97%) |
| B | CNTB | Rademikibart /CBP-201 | Acute Exacerbations in COPD (Seabreeze STAT) | September 2026 | the catalyst date has passed | — | Analysed
view analysis →
Settled: positive — the primary endpoint, treatment failure (death from any cause, (re)admission to hospital for COPD, an emergency-department (re)visit or unscheduled visit for worsening COPD, or intensified pharmacologic treatment) within 28 days of randomisation, was reduced by 81% against placebo, p=0.0122 (labelled preliminary): 2 of 78 (2.6%) on rademikibart against 11 of 81 (13.6%) on placebo, failures counted through the Day 28 visit, which the protocol allows at +/-3 days. The company's count of failures within exactly 28 days gives a 77% reduction, p=0.0373. The arm sizes on the efficacy table are the 159 randomised participants (81 and 78); no analysis population is named. Neither the release nor the deck names the test behind the primary's p-value or states its sidedness; the deck's footnote 'Preliminary p-values based on Fisher's Exact' is attached to the hospital/ED-return figure (7/81 against 0/78, p=0.0137). The key secondary, post-bronchodilator FEV1 at Week 1 (Day 7), was not significant, with a 0 mL difference; the release omits it and reports Week 4 instead (+70 mL, p=0.1607). Reported separately from the asthma topline of 2026-09-15. (+0.39%) |
| C | ALZN | AL001 | Bipolar disease | Q3 2026 | the catalyst date has passed | — | Screened |
| C | CUE | CUE-221 (Anti-IgE Antibody) | Chronic Spontaneous Urticaria (China Ph2) | Q3 2026 | the catalyst date has passed | — | Analysed
view analysis →
Settled: positive — all three CUE-221 dose arms were statistically superior to placebo on the study's primary endpoint (so named in Cue's 8-K and in Shen Lian Biomedical's exchange filing; no registry entry was readable), the proportion of patients with HSS7=0 (no hives over seven days) at Week 12: 4 mg/kg 54% (p<0.005), 2 mg/kg 53% (p<0.005), 1 mg/kg 43% (p<0.05) against placebo 11% (Fisher's exact test, modified intention-to-treat); no treatment-related serious adverse events and no hypersensitivity reactions including anaphylaxis; development continues to a planned Phase 2b/3 in CSU. Omalizumab 300 mg (41%) was not statistically tested against CUE-221 at Week 12. (-20.99%) |
| D | RNTX | LTI-03 | Idiopathic pulmonary fibrosis | Q3 2026 | the catalyst date has passed | — | Screened |
| A | CNTB | Rademikibart /CBP-201 | Asthma (Seabreeze STAT) | Early September 2026 | the catalyst date has passed | — | Analysed
view analysis →
Settled: miss — primary 28-day treatment failure not significant (p=0.153); FEV1 key secondary met (p=0.023) (-36%) |
| A | LGVN | Lomecel-B (laromestrocel) | Hypoplastic Left Heart Syndrome | August 2026 | the catalyst date has passed | — | Analysed
view analysis →
Settled: miss — RVEF primary not met (p=0.8336); MACE and clinical composite not significant (-61.6%) |
| C | BIVI | Bezisterim (NE3107) | Neurological symptoms associated with long COVID | Late Summer 2026 | the catalyst date has passed | — | Screened |
| C | OSTX | OST-HER2 | Pediatric lung metastatic osteosarcoma | Summer 2026 | the catalyst date has passed | — | Screened |
| A | VALN | Shigella4V2 (S4V2) | Prevention of shigellosis | Mid-2026 | the catalyst date has passed | — | |
| B | CNSY | REYOBIQ (Rhenium Re186 Obisbemeda) | Leptomeningeal Metastases (LM) | August 13, 2026 | the catalyst date has passed | — | Screened |